University Of Virginia Hospital is a medicare approved dialysis facility center in Charlottesville, Virginia and it has 38 dialysis stations. It is located in Charlottesville City county at Renal Services, Charlottesville, VA, 22908. You can reach out to the office of University Of Virginia Hospital at (434) 924-5631. This dialysis clinic is managed and/or owned by State Owned. University Of Virginia Hospital has the following ownership type - Non-Profit. It was first certified by medicare in September, 1977. The medicare id for this facility is 490009 and it accepts patients under medicare ESRD program.
| Name | University Of Virginia Hospital |
|---|---|
| Location | Renal Services, Charlottesville, Virginia |
| No. of Dialysis Stations | 38 |
| Medicare ID | 490009 |
| Managed By | State Owned |
| Ownership Type | Non-Profit |
| Late Shifts | Yes |
| Renal Services, Charlottesville, Virginia, 22908 | |
| (434) 924-5631 | |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| NPI Number | 1659487452 |
| Organization Name | Uva Health Sciences Center |
| Doing Business As | Rector & Visitors Of The University Of Virginia |
| Address | 1215 Lee St Charlottesville, Virginia, 22908 |
| Phone Number | (434) 924-0211 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 67% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 22% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 61% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 14% |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 57% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 22% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 53% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 30% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 72% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 106 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 22 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 1 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 121 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1058 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Pediatic patients getting regular hemodialysis at the center | 2 |
| Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 14 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 56 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 479 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 87 |
| Pediatric patients getting regular peritoneal dialysis at the centre | 9 |
| Pediatric patient months included in Kt/V greater than or equal to 1.7 | 53 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at University Of Virginia Hospital with elevated calcium levels.
| Patients with hypercalcemia | 187 |
| Hypercalcemia patient months | 1653 |
| Patients with Serumphosphor | 197 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 25 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 170 |
| Patient months included in arterial venous fistula and catheter summaries | 1053 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 52 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 32 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 169 |
| Hospitalization Rate in facility | 183.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 269.2 |
| Hospitalization Rate: Lower Confidence Limit | 133.1 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at University Of Virginia Hospital were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.8 |
| Readmission Rate: Lower Confidence Limit | 22 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at University Of Virginia Hospital get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .97 (As Expected) |
| SIR: Upper Confidence Limit | 1.64 |
| SIR: Lower Confidence Limit | .52 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether University Of Virginia Hospital's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 149 |
| Transfusion Rate in facility | 46.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 78.7 |
| Transfusion Rate: Lower Confidence Limit | 29 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at University Of Virginia Hospital lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 833 |
| Mortality Rate in facility | 17.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.5 |
| Mortality Rate: Lower Confidence Limit | 14.2 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago
University Of Virginia Hospital Location: Renal Services, Charlottesville, Virginia, 22908 Phone: (434) 924-5631 |
Davita - Charlottesville Location: 1460 Pantops Mountain Pl, Charlottesville, Virginia, 22911 Phone: (434) 979-5997 |
Charlottesville North Dialysis Location: 1800 Timberwood Blvd Ste C, Charlottesville, Virginia, 22911 Phone: (434) 973-8555 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
New research findings published in the March issue of the Journal of the American College of Surgeons indicates that despite similar injury severity, uninsured patients were significantly more likely to die after hospital admission for gunshot injury than were insured patients. This difference could not be attributed to demographics or hospital resource use, and held true even after adjusting for the effects of race, age, gender, and injury severity.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.
› Verified 4 days ago